Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index, and 1 are not checked yet.

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials

Open access
Sáez-Llorens, Xavier, Bandyopadhyay, Ananda S, Gast, Christopher, Leon, Tirza De, DeAntonio, Rodrigo, Jimeno, Jose, Caballero, Maria Isabel, Aguirre, Gabriela, Oberste, M Steven, Weldon, William C, Konopka-Anstadt, Jennifer L, Modlin, John, Bachtiar, Novilia S, Fix, Alan, Konz, John, Clemens, Ralf, Costa Clemens, Sue Ann, Rüttimann, Ricardo · 2021 · The Lancet

Abstract

BACKGROUND: Continued emergence and spread of circulating vaccine-derived type 2 polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus vaccines (OPVs) has stimulated development of two novel type 2 OPV candidates (OPV2-c1 and OPV2-c2) designed to have similar immunogenicity, improved genetic stability, and less potential to reacquire neurovirulence. We aimed to assess safety and immunogenicity of the two novel OPV candidates compared with a monovalent Sabin OPV in children and infants. METHODS: We did two single-centre, multi-site, partly-masked, randomised trials in healthy cohorts of children (aged 1-4 years) and infants (aged 18-22 weeks) in Panama: a control phase 4 study with monovalent Sabin OPV2 before global cessation of monovalent OPV2 use, and a phase 2 study with low and high doses of two novel OPV2 candidates. All participants received one OPV2 vaccination and subsets received two doses 28 days apart. Parents reported solicited and unsolicited adverse events. Type 2 poliovirus neutralising antibodies were measured at days 0, 7, 28, and 56, and stool viral shedding was assessed up to 28 days post-vaccination. Primary objectives were to assess safety in all participants and non-inferiority of novel OPV2 day 28 seroprotection versus monovalent OPV2 in infants (non-inferiority margin 10%). These studies were registered with ClinicalTrials.gov, NCT02521974 and NCT03554798. FINDINGS: The control study took place between Oct 23, 2015, and April 29, 2016, and the subsequent phase 2 study between Sept 19, 2018, and Sept 30, 2019. 150 children (50 in the control study and 100 of 129 assessed for eligibility in the novel OPV2 study) and 684 infants (110 of 114 assessed for eligibility in the control study and 574 of 684 assessed for eligibility in the novel OPV2 study) were enrolled and received at least one study vaccination. Vaccinations were safe and well tolerated with no causally associated serious adverse events or important medical events in any group. Solicited and unsolicited adverse events were overwhelmingly mild or moderate irrespective of vaccine or dose. Nearly all children were seroprotected at baseline, indicating high baseline immunity. In children, the seroprotection rate 28 days after one dose was 100% for monovalent OPV2 and both novel OPV2 candidates. In infants at day 28, 91 (94% [95% CI 87-98]) of 97 were seroprotected after receiving monovalent OPV2, 134 (94% [88-97]) of 143 after high-dose novel OPV2-c1, 122 (93% [87-97]) of 131 after low-dose novel OPV2-c1, 138 (95% [90-98]) of 146 after high-dose novel OPV2-c2, and 115 (91% [84-95]) of 127 after low-dose novel OPV2-c2. Non-inferiority was shown for low-dose and high-dose novel OPV2-c1 and high-dose novel OPV2-c2 despite monovalent OPV2 recipients having higher baseline immunity. INTERPRETATION: Both novel OPV2 candidates were safe, well tolerated, and immunogenic in children and infants. Novel OPV2 could be an important addition to our resources against poliovirus given the current epidemiological situation. FUNDING: Fighting Infectious Diseases in Emerging Countries and Bill & Melinda Gates Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32540-x

Cites

13 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profiles Per-protocol set used for immunogenicity analyses at day 28, and those additionally analysed at day 56 after two doses. OPV2=type 2 oral poliovirus vaccine.
Figure 1 Trial profiles Per-protocol set used for immunogenicity analyses at day 28, and those additionally analysed at day 56 after two doses. OPV2=type 2 oral poliovirus vaccine.CC BY · PubMed Central
Figure 2 Type 2 shedding in children and infants after monovalent OPV2 and high-dose novel OPV2 administration Proportions (with 95% CI) of children (A) and infants (B) shedding poliovirus type 2 (PCR-positive stools) 7, 14, 21, and 28 days after vaccination with monovalent OPV2 or high-dose novel OPV2 candidates. Shedding was compared with the two-sided Fisher's exact test. p values indicated when novel OPV2 data were significantly different versus monovalent OPV2. OPV2=type 2 oral poliovirus vaccine.
Figure 2 Type 2 shedding in children and infants after monovalent OPV2 and high-dose novel OPV2 administration Proportions (with 95% CI) of children (A) and infants (B) shedding poliovirus type 2 (PCR-positive stools) 7, 14, 21, and 28 days after vaccination with monovalent OPV2 or high-dose novel OPV2 candidates. Shedding was compared with the two-sided Fisher's exact test. p values indicated when novel OPV2 data were significantly different versus monovalent OPV2. OPV2=type 2 oral poliovirus vaccine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 1

  1. 2020, Meeting of the strategic advisory group of experts on immunization, 31 March–1 April 2020: conclusions and recommendations: polio, Wkly Epidemiol Rec, 22, 249

Cited by

See all 85

Metadata

Authors
Sáez-Llorens, X., Bandyopadhyay, A. S., Gast, C., Leon, T. D., DeAntonio, R., Jimeno, J., Caballero, M. I., Aguirre, G., Oberste, M. S., Weldon, W. C., Konopka-Anstadt, J. L., Modlin, J., Bachtiar, N. S., Fix, A., Konz, J., Clemens, R., Costa Clemens, S. A., & Rüttimann, R.
Affiliations
  • Gates Foundation (US)
  • Program for Appropriate Technology in Health (US)
  • CEVAXIN (PA)
  • VaxTrials (Panama) (PA)
  • Fighting Infectious Diseases in Emerging Countries (US)
  • Centers for Disease Control and Prevention (US)
  • Dartmouth College (US)
  • PT Bio Farma (Indonesia) (ID)
Corresponding author
Rüttimann, Ricardo
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-01
Volume
397
Issue
10268
Pages
27-38
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4254537929
Cited by
81
References
13
Citations by year
2026: 5 · 2025: 15 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 12
FWCI
7.43
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Greater South Information System
Funders
  • Eli Lilly and Company
  • Centers for Disease Control and Prevention
  • Pan American Health Organization
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
oral polio vaccine, poliovirus type 2, vaccine safety, immunogenicity, vaccine-associated paralytic poliomyelitis, infants, children
MeSH terms
Antibodies, Viral, Antibody Formation, Child, Preschool, Female, Humans, Immunization Schedule, Infant, Male, Panama, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Vaccination, Virus Shedding, Poliovirus, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32540-x
The paper
Sáez-Llorens, X., Bandyopadhyay, A. S., Gast, C., Leon, T. D., DeAntonio, R., Jimeno, J., Caballero, M. I., Aguirre, G., Oberste, M. S., Weldon, W. C., Konopka-Anstadt, J. L., Modlin, J., Bachtiar, N. S., Fix, A., Konz, J., Clemens, R., Costa Clemens, S. A., & Rüttimann, R. (2021). Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. The Lancet. https://doi.org/10.1016/s0140-6736(20)32540-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.